Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting

Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients HOUSTON, April 8, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

The release as fetched from its publisher. moleculin.com ↗